Systemic 7-methylxanthine in retarding axial eye growth and myopia progression: a 36-month pilot study |
| |
Authors: | Klaus Trier Søren Munk Ribel-Madsen Dongmei Cui Søren Brøgger Christensen |
| |
Institution: | 1. Trier Research Laboratories, Tingskiftevej 6, 2900, Hellerup, Denmark 2. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China 3. Department of Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen, Copenhagen, Denmark
|
| |
Abstract: | The adenosine antagonist 7-methylxanthine (7-mx) works against myopia in animal models. In a clinical trial, 68 myopic children (mean age 11.3 years) received either placebo or 7-mx tablets for 12 months. All participants subsequently received 7-mx for another 12 months, after which treatment was stopped. Axial length was measured with Zeiss IOL-Master and cycloplegic refraction with Nikon Retinomax at ?6, 0, 12, 24, and 36 months. Axial growth was reduced among children treated with 7-mx for 24 months compared with those only treated for the last 12 months. Myopia progression and axial eye growth slowed down in periods with 7-mx treatment, but when the treatment was stopped, both myopia progression and axial eye growth continued with invariable speed. The results indicate that 7-mx reduces eye elongation and myopia progression in childhood myopia. The treatment is safe and without side effects and may be continued until 18–20 years of age when myopia progression normally stops. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|